3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Brain Neoplasms
3
Recurrence
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Glioblastoma
2
Carcinoma, Squamous Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Squamous Cell Cancer
1
Rare Tumor
1
Penile Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neoplasms
1
NSCLC
1
Lung Neoplasms
1
Carcinoma
1
Advanced Gastric Cancer
1
Interventions
Oxaliplatin
5
Capecitabine
5
Paclitaxel
4
apatinib
3
Fluorouracil
3
Docetaxel
3
Cisplatin
3
S 1 (combination)
2
Leucovorin
2
titanium silicide
1
rucaparib
1
relatlimab
1
raltitrexed
1
pazopanib
1
olaparib
1
linrodostat
1
endostar protein
1
durvalumab
1
dacomitinib
1
capivasertib
1
camrelizumab
1
Sunitinib
1
SHR-1701
1
Nivolumab
1
Ipilimumab
1
HMPL-013
1
Epirubicin
1
Doxorubicin
1
CF regimen
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Gastric Cancer
×
dacomitinib
×
Clear all
NCT01152853
2015-11-20
PF299804-AGC
Seoul National University Hospital
Phase 2
Completed
28 enrolled